GERON CORP Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value
GERON CORP (GERN) had Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value of $20.23 million as of 2018-06-30, per its 10-Q filed 2018-07-31.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue · last filed 2018-07-31
- 2018-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $20.23M.
- 2018-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $16.50M.
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $13.96M.
- 2017-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $11.47M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value |
|---|---|
| 2018-06-30 | $20.23M 10-Q · filed 2018-07-31 |
| 2018-03-31 | $16.50M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $13.96M 10-Q · filed 2018-07-31 |
| 2017-09-30 | $11.47M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $1.40M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $5.92M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $6.94M 10-K · filed 2018-03-16 |
| 2016-09-30 | $7.58M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $9.13M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $3.40M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $6.30M 10-K · filed 2017-03-01 |
| 2015-09-30 | $2.56M 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |